Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
改进的口服 P-选择素阻滞剂用于预防性镰状细胞病治疗
基本信息
- 批准号:8780313
- 负责人:
- 金额:$ 22.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingActivated Partial Thromboplastin Time measurementAcuteAcute PainAdhesionsAdverse effectsAffectAnticoagulantsBindingBiological AssayBiological AvailabilityBloodBlood VesselsBlood flowCell Adhesion MoleculesCellular AssayCessation of lifeClinicClinical DataClinical TrialsDataDefectDevelopmentDiseaseDoseDrug FormulationsDrug KineticsErythrocytesEventExclusionFactor XaFractionationFrequenciesFunctional disorderGenerationsGoalsGrantHL-60 CellsHemoglobinHeterogeneityHumanImpairmentIn VitroIndividualInheritedLegal patentMacaca fascicularisMarketingModelingMolecularMolecular WeightMonkeysMorbidity - disease rateMusOralP-SelectinPainParentsPatientsPentosan PolysulfatePharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePhasePreclinical TestingPreventionProductionPropertyProphylactic treatmentProthrombin time assayQuality of lifeRadioactivityRadiolabeledRecombinantsSickle CellSickle Cell AnemiaSickle HemoglobinSmall Business Innovation Research GrantSodiumSodium CompoundsSymptomsTestingTherapeuticThrombin Time AssayUnited Statesabsorptionbasecompliance behaviordisabilityhydroxyureaimprovedpillpolymerizationprematurepreventprophylacticpublic health relevanceradiotracerscale upsicklingtheories
项目摘要
DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dire need exists for our drug, as millions of patients who have inherited SCD world-wide, ~100,000 in the US, continue to suffer with episodic pain, disability, and premature death. Hydroxyurea treatment has clear-cut deficiencies, and many drugs under development target treatment rather than prevention of acute events. The cause of most SCD morbidity is abnormal blood flow, notably acute pain crises that result from stoppage of microvascular flow. Defective blood flow results from multiple pathophysiologies, includin several that are independent of the paradigmatic sequence of deoxygenation -> sickle hemoglobin polymerization -> red cell sickling. Based on evidence that endothelial P-selectin is central to ongoing impairment and acute stoppage of flow, we are targeting this adhesion molecule with our therapy. In vitro and preliminary clinical data show that pentosan polysulfate sodium (PPS) improves microvascular blood flow in SCD. However, commercially available PPS is not ideal therapy because of its marginal oral bioavailability and limited duration of action. Accordingly, we have devised two synergetic plans to develop improved second generation PPS-2 that will provide increased oral bioavailability so all patients will receive therapeutic amounts of PPS and prolonged absorption so that the frequency of PPS administration will be reduced and patient compliance enhanced. One plan employs direct formulation of parent PPS; the other employs fractionation of PPS, identification of pharmaceutically superior PPS fractions, and formulation of the optimal fraction. This proposal focuses on the fractionation strategy. Lower molecular weight PPS fractions have better oral bioavailability and less anticoagulant activity than unfractionated PPS. We first will test PPS fractions of different molecular weighs to identify the two lowest molecular weight fractions that have robust P-selectin blocking activity
and safe anticoagulant activity. Then we will test those two for oral bioavailability and pharmacokinetics in monkeys, the best nonhuman model of human bioavailability and pharmacokinetics. These studies will use high doses of radiolabeled PPS compounds to obtain the best bioavailability/pharmacokinetic data for PPS to date and first such dat for PPS fractions. These studies will identify the most favorable PPS fraction to be formulated and developed as PPS-2 and will enable filing a composition of matter patent. Our overarching goal is to improve the quality of life of SCD patients by bringing to market an effective oral P-selectin blocking drug for long-term administration to prevent sickle red blood cell sticking to the lining of blood vessels, improve blood flw, and avert acute painful episodes. This Phase I SBIR will provide a superior PPS fraction for PPS-2 formulation and development. Subsequent fractionation, formulation, preclinical testing in vitro and in sickle cell mice, GMP production, and IND filing ill be achieved with support of a Phase II SBIR grant.
描述(由申请人提供):镰状细胞疾病(SCD)是一种不良治疗的衰弱状况,我们正在开发一种有希望的新口服预防性疗法。我们的药物存在可怕的需求,因为数百万在全球遗传了SCD的患者,在美国约有100,000名患者,继续患有情节性疼痛,残疾和过早死亡。 羟基脲治疗具有明显的缺陷,许多正在开发目标治疗的药物,而不是预防急性事件。大多数SCD发病率的原因是血流异常,特别是由于微血管流量停止而导致的急性疼痛危机。 血流有缺陷来自多种病理生理,其中包括几种独立于去氧合的范式序列 - >镰状血红蛋白聚合 - >红细胞疾病。基于证据表明内皮P-选择素对持续的损伤和流动急性停止至关重要,我们将其靶向这种粘附分子。 体外和初步临床数据表明,五峰多硫酸钠(PPS)改善了SCD中的微血管血流。 但是,由于其边际口服生物利用度和有限的作用持续时间,市售PPS并不是理想的治疗。因此,我们已经设计了两个协同计划,以开发改进的第二代PPS-2,这些计划将提供增加的口服生物利用度,以便所有患者都将获得治疗量的PPS和延长的吸收,因此PPS给药的频率将降低并提高患者合规性。 一个计划采用直接配方父pps; 另一种采用PPS的分级,药物优质pps分数的鉴定以及最佳分数的配方。 该提案侧重于分馏策略。 较低的分子量PPS分数比未分流的PPS具有更好的口服生物利用度和抗凝活性更低。 我们首先将测试不同分子称重的PPS级分,以识别具有强大P-选择蛋白阻断活性的两个最低分子量分数
和安全的抗凝活性。然后,我们将测试这两种猴子的口服生物利用度和药代动力学,这是人类生物利用度和药代动力学的最佳非人类模型。 这些研究将使用高剂量的放射性标记的PPS化合物来获得迄今为止PPS的最佳生物利用度/药代动力学数据,首先是PPS级分的DAT。 这些研究将确定要作为PPS-2制定和开发的最有利的PPS分数,并能够提交物质专利的组成。 我们的总体目标是通过将有效的口服P-选择蛋白阻断药物推销长期给药,以防止镰状红细胞粘在血管内膜上,改善血液FLW并避免急性疼痛发作,从而改善SCD患者的生活质量。 I阶段I SBIR将为PPS-2公式和开发提供优质的PPS分数。 随后的分馏,配方,体外和镰状细胞小鼠的临床前测试,GMP的产生和IND归档,可以支持II期SBIR赠款。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen H. Embury其他文献
Human Embryonic ζ-Globin Chains in Fetal and Newborn Blood
- DOI:
10.1182/blood.v74.4.1409.1409 - 发表时间:
1989-09-01 - 期刊:
- 影响因子:
- 作者:
David H.K. Chui;William C. Mentzer;Margaret Patterson;Terri A. Iarocci;Stephen H. Embury;Susan P. Perrine;Reuben S. Mibashan;Douglas R. Higgs - 通讯作者:
Douglas R. Higgs
Southern Society for Clinical Investigation: Constitution, Bylaws, and Amendments
- DOI:
10.1016/s0002-9629(15)40813-4 - 发表时间:
2000-09-01 - 期刊:
- 影响因子:
- 作者:
Stephen H. Embury - 通讯作者:
Stephen H. Embury
Presentation of the Southern Society for Clinical Investigation Founders Medal to Dr. Martin Steinberg
- DOI:
10.1016/s0002-9629(15)40810-9 - 发表时间:
2000-09-01 - 期刊:
- 影响因子:
- 作者:
Stephen H. Embury - 通讯作者:
Stephen H. Embury
The Leftward Deletion α-Thal-2 Haplotype in a Black Subject With Hemoglobin SS
- DOI:
10.1182/blood.v65.3.769.769 - 发表时间:
1985-03-01 - 期刊:
- 影响因子:
- 作者:
Stephen H. Embury;Mary Ann Gholson;Peter Gillette;Ronald F. Rieder;the National Cooperative Study of Sickle Cell Disease - 通讯作者:
the National Cooperative Study of Sickle Cell Disease
Selective Enzymatic Amplification of α<sub>2</sub>-Globin DNA for Detection of the Hemoglobin Constant Spring Mutation
- DOI:
10.1182/blood.v73.7.1987.1987 - 发表时间:
1989-05-15 - 期刊:
- 影响因子:
- 作者:
Gerald L. Kropp;Suthat Fucharoen;Stephen H. Embury - 通讯作者:
Stephen H. Embury
Stephen H. Embury的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen H. Embury', 18)}}的其他基金
Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
改进的口服 P-选择素阻滞剂用于预防性镰状细胞病治疗
- 批准号:
9202918 - 财政年份:2014
- 资助金额:
$ 22.6万 - 项目类别:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
SC 血管闭塞中的活化内皮粘附力
- 批准号:
6617851 - 财政年份:2000
- 资助金额:
$ 22.6万 - 项目类别:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
SC 血管闭塞中的活化内皮粘附力
- 批准号:
6062396 - 财政年份:2000
- 资助金额:
$ 22.6万 - 项目类别:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
SC 血管闭塞中的活化内皮粘附力
- 批准号:
6390650 - 财政年份:2000
- 资助金额:
$ 22.6万 - 项目类别:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
SC 血管闭塞中的活化内皮粘附力
- 批准号:
6527377 - 财政年份:2000
- 资助金额:
$ 22.6万 - 项目类别:
ENDOTHELIAL CELL REACTIVITY IN SICKLE CELL VASOOCCLUSION
镰状细胞血管闭塞中的内皮细胞反应性
- 批准号:
6325901 - 财政年份:2000
- 资助金额:
$ 22.6万 - 项目类别:
ENDOTHELIAL CELL REACTIVITY IN SICKLE CELL VASOOCCLUSION
镰状细胞血管闭塞中的内皮细胞反应性
- 批准号:
6109522 - 财政年份:1999
- 资助金额:
$ 22.6万 - 项目类别:
ENDOTHELIAL CELL REACTIVITY IN SICKLE CELL VASOOCCLUSION
镰状细胞血管闭塞中的内皮细胞反应性
- 批准号:
6272592 - 财政年份:1998
- 资助金额:
$ 22.6万 - 项目类别:
CORE--DNA DIAGNOSTIC LABORATORY AND WEST BAY COMPONENTS--HEMOGLOBINOPATHY LAB
核心——DNA诊断实验室和西湾组成部分——血红蛋白病实验室
- 批准号:
6241648 - 财政年份:1997
- 资助金额:
$ 22.6万 - 项目类别:
相似海外基金
Novel risk stratification score for patients presenting with acute Cerebral Venous Sinus Thrombosis
急性脑静脉窦血栓形成患者的新风险分层评分
- 批准号:
10592974 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease
PAR1 的变构调节用于治疗镰状细胞病
- 批准号:
10699379 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients
用于快速综合评估创伤患者凝血功能的近患者低血容量平台
- 批准号:
10697216 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
多功能抗血栓治疗冠状动脉微血管阻塞
- 批准号:
10696319 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability
逆转感染性休克并恢复血流动力学稳定性的新型体外疗法
- 批准号:
10374283 - 财政年份:2022
- 资助金额:
$ 22.6万 - 项目类别: